Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

582
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
582
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

439
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
439
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

274
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
274

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic testing among patients evaluated for epilepsy surgery.

Epileptic disorders : international epilepsy journal with videotape·2026
Same author

Information needs of patients considering epilepsy surgery: A scoping review.

Epilepsia·2026
Same author

Comparison of Consumer Smartwatch and Research-Grade Accelerometer-Derived Step Counts in Amyotrophic Lateral Sclerosis.

Muscle & nerve·2026
Same author

Transcriptome Profiling of Induced Sputum Identified Upregulated TNF-α/NF-κB Signalling and Downregulated Mitochondrial Respiratory Chain Function in Post-Infectious Bronchiolitis Obliterans.

Biomolecules·2026
Same author

Low diagnostic yield of presurgical genetic testing in adult patients with epilepsy.

Epilepsia·2026
Same author

A translational multimodal machine-learning prototype predicting valproate response in epilepsy treatment.

Epilepsia·2026

Related Experiment Video

Updated: Sep 9, 2025

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

489

A translational multimodal machine-learning prototype predicting valproate response in epilepsy treatment.

Simeon Platte1, Afsheen Kumar1, Giorgia Guerini2

  • 1Goethe University Frankfurt, University Hospital, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Frankfurt, Germany.

Medrxiv : the Preprint Server for Health Sciences
|September 5, 2025
PubMed
Summary

This study developed a predictive algorithm using genetic and in-vitro data to personalize Valproic Acid (VPA) treatment for epilepsy, aiming to improve seizure control and reduce adverse reactions.

Keywords:
Antiseizure medicationsBiomarker-based Machine Learning ClassifierPersonalized treatment

More Related Videos

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.3K
Statistical Modelling of Cortical Connectivity Using Non-invasive Electroencephalograms
08:51

Statistical Modelling of Cortical Connectivity Using Non-invasive Electroencephalograms

Published on: November 1, 2019

5.7K

Related Experiment Videos

Last Updated: Sep 9, 2025

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

489
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.3K
Statistical Modelling of Cortical Connectivity Using Non-invasive Electroencephalograms
08:51

Statistical Modelling of Cortical Connectivity Using Non-invasive Electroencephalograms

Published on: November 1, 2019

5.7K

Area of Science:

  • Pharmacogenomics
  • Neuroscience
  • Computational Biology

Background:

  • Epilepsy impacts 1% of the global population, often requiring long-term antiseizure medication (ASM) treatment.
  • Current ASM selection relies on trial and error, with only 50% of patients achieving sustained seizure freedom on first-line treatments.
  • Valproic Acid (VPA), a common first-line ASM, shows suboptimal efficacy and tolerability in nearly 50% of patients, leading to inadequate seizure control (ISC) or unacceptable adverse reactions (UARs).

Purpose of the Study:

  • To develop and validate a predictive algorithm for optimizing Valproic Acid (VPA) treatment decisions in epilepsy patients.
  • To integrate multimodal data, including in-vitro neuronal response and genetic variations, for personalized VPA therapy.
  • To reduce treatment delays, patient burden, and healthcare costs associated with suboptimal VPA therapy.

Main Methods:

  • Developed a predictive algorithm integrating in-vitro data, genetic variations (common and rare), and prior knowledge.
  • Utilized a multimodal pipeline focusing on genes related to VPA pharmacodynamics and pharmacokinetics.
  • Trained and validated the algorithm using multi-ethnic datasets and the Epi25 cohort, with proof-of-concept validation on an independent cohort.

Main Results:

  • The predictive algorithm demonstrated modest overall performance but highlighted potential clinical value through prediction accuracy and high negative predictive value.
  • The model showed potential to significantly reduce the time to successful VPA treatment.
  • Estimated reduction in patient burden and healthcare costs associated with epilepsy management.

Conclusions:

  • A translational biomarker-based algorithm shows promise for personalizing VPA treatment in epilepsy, moving beyond a one-size-fits-all approach.
  • The developed prototype, while not yet clinically ready due to data requirements (SNP and WES), indicates a viable path toward enhanced treatment efficacy.
  • Personalized VPA therapy can improve quality of life by shortening the time to seizure freedom and minimizing ISC and UARs.